Direxion Daily CSI China Internet Bull 2X Shares vs Eli Lilly And Co — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $24.55, while Eli Lilly And Co trades at $1,215.54 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals.
| CWEB | LLY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $1.24K |
52-Week Low | $17.70 | $635.22 |
Market Cap | — | $1.10T |
Enterprise Value | — | $1.14T |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.
The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Trailing returns across standard periods
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →